RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:2382

Lennox-Gastaut syndrome

medium confidenceDisorder

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

5,401

96.7th percentile

Trials

48

Interventional, condition-specific

Researchers

1,152

Distinct authors in sample

Gene link

MAPK10

Limited

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare, severe early-onset developmental epileptic characterized by the triad of intellectual impairment, multiple seizure types, and typical electroencephalography (EEG) abnormalities.

How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

LGS

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Limited — MAPK10

  2. LiteraturePresent

    5,401 matched papers (3,512 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    48 matched on ClinicalTrials.gov (8 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Possibly — only limited evidence so far for MAPK10.

GenCC classification: Limited.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

5,401

5,401 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

5,401 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

3,512 in the last 10 years · medium confidence · 96.7th percentile (publications denominator)

Phrase hits: 5,401 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,152

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Samanta D17 papers · 2026

    Division of Child Neurology, Department of Pediatrics, University of Arkansas for Medical Sciences, 1 Children's Way, Little Rock, AR 72202, USA.

    Papers in Europe PMC
  2. 02
    Dixon-Salazar T8 papers · 2026

    Lennox-Gastaut Syndrome Foundation, San Diego, CA, USA.

    Papers in Europe PMC
  3. 03
    Auvin S7 papers · 2026

    APHP, Robert Debré University Hospital, Pediatric Neurology Department, CRMR epilepsies rares, EpiCare Member, Paris, France.

    Papers in Europe PMC
  4. 04
    Striano P7 papers · 2026

    IRCCS Istituto Giannina Gaslini, Full Member of ERN EpiCARE, Genova, Italy.

    Papers in Europe PMC
  5. 05
    Coppola A6 papers · 2026

    Epilepsy Center, University Hospital Federico II, Naples, Italy.

    Papers in Europe PMC
  6. 06
    Patel AD6 papers · 2026

    Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA; The Center for Clinical Excellence, Nationwide Children's Hospital, Columbus, OH, USA.

    Papers in Europe PMC
  7. 07
    Warren AEL6 papers · 2026

    Department of Neurosurgery, Mass General Brigham, Harvard Medical School, Boston, MA 02115, USA.

    Papers in Europe PMC
  8. 08
    Andrews JS5 papers · 2026

    Takeda Development Center Americas, Inc., 350 Massachusetts Avenue, Cambridge, MA, 02139, USA.

    Papers in Europe PMC
  9. 09
    Battaglia DI5 papers · 2026

    Pediatric Neurology and Psychiatric Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

    Papers in Europe PMC
  10. 10
    Di Bonaventura C5 papers · 2026

    Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

48

interventional trials for this specific condition

48 interventional trials matched this specific condition name; 8 currently recruiting in our sample.

Data as of 27 July 2026

48 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 97th percentile).

medium confidence · 97th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

48 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

9 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Lennox-Gastaut syndrome"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Lennox-Gastaut syndrome" OR "MAPK10"

Recall-expansion terms: MAPK10

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 48 interventional · 9 observational · 3 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: LGS

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T20:02:41.136Z